Cargando…

The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats

RATIONALE: Development and progression of cardiovascular diseases, including hypertension, are often associated with impaired nitric oxide synthase (NOS) function and nitric oxide (NO) deficiency. Current treatment strategies to restore NO bioavailability with organic nitrates are hampered by undesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Paulo, Luciano L., Cruz, Josiane Campos, Zhuge, Zhengbing, Carvalho-Galvão, Alynne, Brandão, Maria C.R., Diniz, Thiago F., Haworth, Sarah McCann, Athayde-Filho, Petrônio F., Lemos, Virginia S., Lundberg, Jon O., Montenegro, Marcelo F., Braga, Valdir A., Carlström, Mattias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735329/
https://www.ncbi.nlm.nih.gov/pubmed/29268201
http://dx.doi.org/10.1016/j.redox.2017.12.004
_version_ 1783287185223450624
author Paulo, Luciano L.
Cruz, Josiane Campos
Zhuge, Zhengbing
Carvalho-Galvão, Alynne
Brandão, Maria C.R.
Diniz, Thiago F.
Haworth, Sarah McCann
Athayde-Filho, Petrônio F.
Lemos, Virginia S.
Lundberg, Jon O.
Montenegro, Marcelo F.
Braga, Valdir A.
Carlström, Mattias
author_facet Paulo, Luciano L.
Cruz, Josiane Campos
Zhuge, Zhengbing
Carvalho-Galvão, Alynne
Brandão, Maria C.R.
Diniz, Thiago F.
Haworth, Sarah McCann
Athayde-Filho, Petrônio F.
Lemos, Virginia S.
Lundberg, Jon O.
Montenegro, Marcelo F.
Braga, Valdir A.
Carlström, Mattias
author_sort Paulo, Luciano L.
collection PubMed
description RATIONALE: Development and progression of cardiovascular diseases, including hypertension, are often associated with impaired nitric oxide synthase (NOS) function and nitric oxide (NO) deficiency. Current treatment strategies to restore NO bioavailability with organic nitrates are hampered by undesirable side effects and development of tolerance. In this study, we evaluated NO release capability and cardiovascular effects of the newly synthesized organic nitrate 1, 3-bis (hexyloxy) propan-2-yl nitrate (NDHP). METHODS: A combination of in vitro and in vivo approaches was utilized to assess acute effects of NDHP on NO release, vascular reactivity and blood pressure. The therapeutic value of chronic NDHP treatment was assessed in an experimental model of angiotensin II-induced hypertension in combination with NOS inhibition. RESULTS: NDHP mediates NO formation in both cell-free system and small resistance arteries, a process which is catalyzed by xanthine oxidoreductase. NDHP-induced vasorelaxation is endothelium independent and mediated by NO release and modulation of potassium channels. Reduction of blood pressure following acute intravenous infusion of NDHP was more pronounced in hypertensive rats (two-kidney-one-clip model) than in normotensive sham-operated rats. Toxicological tests did not reveal any harmful effects following treatment with high doses of NDHP. Finally, chronic treatment with NDHP significantly attenuated the development of hypertension and endothelial dysfunction in rats with chronic NOS inhibition and angiotensin II infusion. CONCLUSION: Acute treatment with the novel organic nitrate NDHP increases NO formation, which is associated with vasorelaxation and a significant reduction of blood pressure in hypertensive animals. Chronic NDHP treatment attenuates the progression of hypertension and endothelial dysfunction, suggesting a potential for therapeutic applications in cardiovascular disease.
format Online
Article
Text
id pubmed-5735329
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-57353292017-12-21 The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats Paulo, Luciano L. Cruz, Josiane Campos Zhuge, Zhengbing Carvalho-Galvão, Alynne Brandão, Maria C.R. Diniz, Thiago F. Haworth, Sarah McCann Athayde-Filho, Petrônio F. Lemos, Virginia S. Lundberg, Jon O. Montenegro, Marcelo F. Braga, Valdir A. Carlström, Mattias Redox Biol Research Paper RATIONALE: Development and progression of cardiovascular diseases, including hypertension, are often associated with impaired nitric oxide synthase (NOS) function and nitric oxide (NO) deficiency. Current treatment strategies to restore NO bioavailability with organic nitrates are hampered by undesirable side effects and development of tolerance. In this study, we evaluated NO release capability and cardiovascular effects of the newly synthesized organic nitrate 1, 3-bis (hexyloxy) propan-2-yl nitrate (NDHP). METHODS: A combination of in vitro and in vivo approaches was utilized to assess acute effects of NDHP on NO release, vascular reactivity and blood pressure. The therapeutic value of chronic NDHP treatment was assessed in an experimental model of angiotensin II-induced hypertension in combination with NOS inhibition. RESULTS: NDHP mediates NO formation in both cell-free system and small resistance arteries, a process which is catalyzed by xanthine oxidoreductase. NDHP-induced vasorelaxation is endothelium independent and mediated by NO release and modulation of potassium channels. Reduction of blood pressure following acute intravenous infusion of NDHP was more pronounced in hypertensive rats (two-kidney-one-clip model) than in normotensive sham-operated rats. Toxicological tests did not reveal any harmful effects following treatment with high doses of NDHP. Finally, chronic treatment with NDHP significantly attenuated the development of hypertension and endothelial dysfunction in rats with chronic NOS inhibition and angiotensin II infusion. CONCLUSION: Acute treatment with the novel organic nitrate NDHP increases NO formation, which is associated with vasorelaxation and a significant reduction of blood pressure in hypertensive animals. Chronic NDHP treatment attenuates the progression of hypertension and endothelial dysfunction, suggesting a potential for therapeutic applications in cardiovascular disease. Elsevier 2017-12-11 /pmc/articles/PMC5735329/ /pubmed/29268201 http://dx.doi.org/10.1016/j.redox.2017.12.004 Text en © 2017 Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Paulo, Luciano L.
Cruz, Josiane Campos
Zhuge, Zhengbing
Carvalho-Galvão, Alynne
Brandão, Maria C.R.
Diniz, Thiago F.
Haworth, Sarah McCann
Athayde-Filho, Petrônio F.
Lemos, Virginia S.
Lundberg, Jon O.
Montenegro, Marcelo F.
Braga, Valdir A.
Carlström, Mattias
The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats
title The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats
title_full The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats
title_fullStr The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats
title_full_unstemmed The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats
title_short The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats
title_sort novel organic mononitrate ndhp attenuates hypertension and endothelial dysfunction in hypertensive rats
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735329/
https://www.ncbi.nlm.nih.gov/pubmed/29268201
http://dx.doi.org/10.1016/j.redox.2017.12.004
work_keys_str_mv AT paulolucianol thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT cruzjosianecampos thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT zhugezhengbing thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT carvalhogalvaoalynne thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT brandaomariacr thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT dinizthiagof thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT haworthsarahmccann thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT athaydefilhopetroniof thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT lemosvirginias thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT lundbergjono thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT montenegromarcelof thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT bragavaldira thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT carlstrommattias thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT paulolucianol novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT cruzjosianecampos novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT zhugezhengbing novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT carvalhogalvaoalynne novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT brandaomariacr novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT dinizthiagof novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT haworthsarahmccann novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT athaydefilhopetroniof novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT lemosvirginias novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT lundbergjono novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT montenegromarcelof novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT bragavaldira novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats
AT carlstrommattias novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats